GB201701239D0 - Novel formulation - Google Patents

Novel formulation

Info

Publication number
GB201701239D0
GB201701239D0 GBGB1701239.4A GB201701239A GB201701239D0 GB 201701239 D0 GB201701239 D0 GB 201701239D0 GB 201701239 A GB201701239 A GB 201701239A GB 201701239 D0 GB201701239 D0 GB 201701239D0
Authority
GB
United Kingdom
Prior art keywords
novel formulation
formulation
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1701239.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to GBGB1701239.4A priority Critical patent/GB201701239D0/en
Publication of GB201701239D0 publication Critical patent/GB201701239D0/en
Priority to CN201880021100.9A priority patent/CN110430867B/zh
Priority to BE2018/5040A priority patent/BE1025187B1/fr
Priority to BR112019015245A priority patent/BR112019015245A2/pt
Priority to CA3050629A priority patent/CA3050629A1/en
Priority to EP18703633.0A priority patent/EP3573598A1/en
Priority to PCT/IB2018/050453 priority patent/WO2018138667A1/en
Priority to MX2019008798A priority patent/MX2019008798A/es
Priority to JP2019539953A priority patent/JP7090089B2/ja
Priority to US16/478,232 priority patent/US11590243B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10111—Atadenovirus, e.g. ovine adenovirus D
    • C12N2710/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10111—Atadenovirus, e.g. ovine adenovirus D
    • C12N2710/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Manufacturing & Machinery (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB1701239.4A 2017-01-25 2017-01-25 Novel formulation Ceased GB201701239D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB1701239.4A GB201701239D0 (en) 2017-01-25 2017-01-25 Novel formulation
US16/478,232 US11590243B2 (en) 2017-01-25 2018-01-25 Formulation
CA3050629A CA3050629A1 (en) 2017-01-25 2018-01-25 Novel formulation
BE2018/5040A BE1025187B1 (fr) 2017-01-25 2018-01-25 Nouvelle formulation
BR112019015245A BR112019015245A2 (pt) 2017-01-25 2018-01-25 composição, kit, mistura aquosa, e, método para preparação da composição.
CN201880021100.9A CN110430867B (zh) 2017-01-25 2018-01-25 从水性混合物冷冻干燥的组合物及其制备方法
EP18703633.0A EP3573598A1 (en) 2017-01-25 2018-01-25 Novel formulation
PCT/IB2018/050453 WO2018138667A1 (en) 2017-01-25 2018-01-25 Novel formulation
MX2019008798A MX2019008798A (es) 2017-01-25 2018-01-25 Nueva formulacion.
JP2019539953A JP7090089B2 (ja) 2017-01-25 2018-01-25 新規配合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1701239.4A GB201701239D0 (en) 2017-01-25 2017-01-25 Novel formulation

Publications (1)

Publication Number Publication Date
GB201701239D0 true GB201701239D0 (en) 2017-03-08

Family

ID=58462949

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1701239.4A Ceased GB201701239D0 (en) 2017-01-25 2017-01-25 Novel formulation

Country Status (10)

Country Link
US (1) US11590243B2 (enExample)
EP (1) EP3573598A1 (enExample)
JP (1) JP7090089B2 (enExample)
CN (1) CN110430867B (enExample)
BE (1) BE1025187B1 (enExample)
BR (1) BR112019015245A2 (enExample)
CA (1) CA3050629A1 (enExample)
GB (1) GB201701239D0 (enExample)
MX (1) MX2019008798A (enExample)
WO (1) WO2018138667A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201513010D0 (en) * 2015-07-23 2015-09-09 Glaxosmithkline Biolog Sa Novel formulation
EP3587581A1 (en) * 2018-06-26 2020-01-01 GlaxoSmithKline Biologicals S.A. Formulations for simian adenoviral vectors having enhanced storage stability
BR112021025025A2 (pt) * 2019-06-11 2022-02-22 Glaxosmithkline Biologicals Sa Formulações de vacinas de mucosa
JP2023548838A (ja) * 2020-10-29 2023-11-21 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド ニワトリ貧血ウイルス（ｃａｖ）に基づくベクター
US20230414516A1 (en) * 2020-11-16 2023-12-28 BioNTech SE Enhanced formulation stabilization and improved lyophilization processes
CN116782889A (zh) * 2020-11-16 2023-09-19 生物技术欧洲股份公司 增强的制剂稳定性和改善的冻干工艺
CN114903922B (zh) * 2021-02-09 2024-04-26 武汉博沃生物科技有限公司 包含腺病毒的医药配制品及其保存方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
US7456009B2 (en) * 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
SI1409012T1 (sl) 2001-06-22 2009-08-31 Wistar Inst Postopki za induciranje citotoksičnega imunskega odziva in za to uporabni sestavki rekombinantnih opičjih adenovirusov
WO2005071093A2 (en) 2004-01-23 2005-08-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Chimpanzee adenovirus vaccine carriers
PT1954308E (pt) 2005-09-16 2011-11-03 Merial Ltd Estabilizadores para vacinas liofilizadas
EA021391B1 (ru) 2007-03-02 2015-06-30 Глаксосмитклайн Байолоджикалс С.А. Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
SI2391638T1 (sl) 2009-02-02 2018-10-30 Glaxosmithkline Biologicals Sa Nukleinskokislinske in aminokislinske sekvence opičjega adenovirusa, vektorji, ki le-te vsebujejo, in njihova uporaba
CN102028954B (zh) 2009-09-29 2012-11-07 成都康弘生物科技有限公司 一种重组腺病毒的制剂
US9526777B2 (en) 2010-04-16 2016-12-27 The United States Of America As Represented By The Department Of Health And Human Services Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein
WO2012089231A1 (en) 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
BR112014008167B1 (pt) 2011-10-05 2022-05-24 Genvec Inc Adenovírus ou vetor adenoviral e composição os compreendendo
CN107574154A (zh) 2011-10-05 2018-01-12 金维克有限公司 猴(大猩猩)腺病毒或腺病毒载体及其使用方法
CN103974970B (zh) 2011-10-05 2018-01-02 金维克有限公司 猴腺病毒(大猩猩)或腺病毒载体及其使用方法
CN102631672B (zh) 2012-04-27 2014-04-02 天津百若克医药生物技术有限责任公司 一种冻干灭活乙型脑炎疫苗
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
JP6664338B2 (ja) 2014-06-13 2020-03-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組合せ物

Also Published As

Publication number Publication date
US20190365930A1 (en) 2019-12-05
WO2018138667A1 (en) 2018-08-02
CA3050629A1 (en) 2018-08-02
CN110430867A (zh) 2019-11-08
EP3573598A1 (en) 2019-12-04
BR112019015245A2 (pt) 2020-04-14
JP2020506691A (ja) 2020-03-05
JP7090089B2 (ja) 2022-06-23
US11590243B2 (en) 2023-02-28
CN110430867B (zh) 2023-04-07
BE1025187B1 (fr) 2018-12-03
MX2019008798A (es) 2019-09-11
BE1025187A1 (fr) 2018-11-27

Similar Documents

Publication Publication Date Title
GB2551985B (en) Novel formulation
GB201513010D0 (en) Novel formulation
IL274139A (en) Sprayable formulation
GB201707930D0 (en) Formulation component
GB201801614D0 (en) Formulation
GB201701239D0 (en) Novel formulation
GB201707189D0 (en) Novel formulations
GB201816447D0 (en) Formulation
IL274719A (en) formulation
GB201817859D0 (en) Aerosolisable formulation
GB201817862D0 (en) Aerosolisable formulation
GB201707188D0 (en) Novel formulations
GB201713724D0 (en) Formulation
GB201608356D0 (en) Formulation
GB201706969D0 (en) Formulation
GB201707187D0 (en) Novel formulations
GB201813229D0 (en) Formulation
GB201811926D0 (en) Aerosolisable formulation
GB201719464D0 (en) Formulation
GB201807312D0 (en) Formulation
GB201707615D0 (en) Formulation
GB2568045B (en) Formulation
GB201719411D0 (en) Novel formulation
GB201719377D0 (en) Novel formulation
GB201719410D0 (en) Novel formulation

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)